111 related articles for article (PubMed ID: 2523957)
1. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
Hesketh PJ; Murphy WK; Lester EP; Gandara DR; Khojasteh A; Tapazoglou E; Sartiano GP; White DR; Werner K; Chubb JM
J Clin Oncol; 1989 Jun; 7(6):700-5. PubMed ID: 2523957
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
Cubeddu LX; Hoffmann IS; Fuenmayor NT; Finn AL
N Engl J Med; 1990 Mar; 322(12):810-6. PubMed ID: 1689807
[TBL] [Abstract][Full Text] [Related]
3. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.
Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G
J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739
[TBL] [Abstract][Full Text] [Related]
4. Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
Grunberg SM; Stevenson LL; Russell CA; McDermed JE
J Clin Oncol; 1989 Aug; 7(8):1137-41. PubMed ID: 2526864
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis.
Marty M; Pouillart P; Scholl S; Droz JP; Azab M; Brion N; Pujade-Lauraine E; Paule B; Paes D; Bons J
N Engl J Med; 1990 Mar; 322(12):816-21. PubMed ID: 2137902
[TBL] [Abstract][Full Text] [Related]
6. Ondansetron (GR 38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy.
Hainsworth JD; Omura GA; Khojasteh A; Bryson JC; Finn AL
Am J Clin Oncol; 1991 Aug; 14(4):336-40. PubMed ID: 1830716
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.
Fraschini G; Ciociola A; Esparza L; Templeton D; Holmes FA; Walters RS; Hortobagyi GN
J Clin Oncol; 1991 Jul; 9(7):1268-74. PubMed ID: 1828499
[TBL] [Abstract][Full Text] [Related]
8. Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
Kris MG; Gralla RJ; Clark RA; Tyson LB
J Clin Oncol; 1988 Apr; 6(4):659-62. PubMed ID: 2965755
[TBL] [Abstract][Full Text] [Related]
9. Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy.
Einhorn LH; Nagy C; Werner K; Finn AL
J Clin Oncol; 1990 Apr; 8(4):731-5. PubMed ID: 2138214
[TBL] [Abstract][Full Text] [Related]
10. Ondansetron: prevention of nausea & vomiting in cisplatin based chemotherapy.
Cheirsilpa A; Ratanatharathorn V; Sinlarat P; Chindavijak K; Lousoontornsiri W; Chakrapee-Sirisuk S; Srimuninimit V
J Med Assoc Thai; 1994 Apr; 77(4):201-6. PubMed ID: 7844494
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
[TBL] [Abstract][Full Text] [Related]
12. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.
Beck TM; Hesketh PJ; Madajewicz S; Navari RM; Pendergrass K; Lester EP; Kish JA; Murphy WK; Hainsworth JD; Gandara DR
J Clin Oncol; 1992 Dec; 10(12):1969-75. PubMed ID: 1453211
[TBL] [Abstract][Full Text] [Related]
13. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.
Hesketh P; Navari R; Grote T; Gralla R; Hainsworth J; Kris M; Anthony L; Khojasteh A; Tapazoglou E; Benedict C; Hahne W
J Clin Oncol; 1996 Aug; 14(8):2242-9. PubMed ID: 8708713
[TBL] [Abstract][Full Text] [Related]
14. Ondansetron for the prevention of emesis induced by high-dose cisplatin. A multi-center dose-response study.
Khojasteh A; Sartiano G; Tapazoglou E; Lester E; Gandara D; Bernard S; Finn A
Cancer; 1990 Sep; 66(6):1101-5. PubMed ID: 2144788
[TBL] [Abstract][Full Text] [Related]
15. Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Kris MG; Tyson LB; Clark RA; Gralla RJ
Cancer; 1992 Aug; 70(4 Suppl):1012-6. PubMed ID: 1386282
[TBL] [Abstract][Full Text] [Related]
16. [Refractory vomiting with cisplatin therapy. Prospective study with the serotonin receptor antagonist GR 38032F].
du Bois A; Meerpohl HG; Wilhelm C; Quaas L; Barnickel I; Pfleiderer A
Onkologie; 1990 Oct; 13(5):364-8. PubMed ID: 2150551
[TBL] [Abstract][Full Text] [Related]
17. Single-dose ondansetron for the prevention of cisplatin-induced emesis: efficacy results.
Hainsworth JD; Hesketh PJ
Semin Oncol; 1992 Dec; 19(6 Suppl 15):14-9. PubMed ID: 1485176
[TBL] [Abstract][Full Text] [Related]
18. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
[TBL] [Abstract][Full Text] [Related]
19. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
